Catheter Precision, Inc. Announces Completion of VIVO European Registry Patient Follow-up and New Evaluations

FORT MILL, SC / ACCESSWIRE / July 16, 2024 / Catheter Precision, Inc. (NYSE American:VTAK) has announced the completion of the patient follow-up phase for the VIVO European Registry. The registry began in October 2021 and concluded patient enrollment in June 2023, involving 125 patients.

The aim was to gather real-world data on the VIVO device's effectiveness outside a clinical trial. This data will help meet European regulatory requirements, publish multi-center data, and support future studies and improvements for VIVO. The data is expected to become available in Q4 2024. Meanwhile, Catheter Precision continues other ongoing studies for its VIVO and LockeT product lines.

The company also revealed that three new European hospitals and two U.S. hospitals will begin initial VIVO product evaluations this month.